• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Omadacycline for the treatment of infections: Case series and review of the literature.奥马环素用于治疗感染：病例系列及文献综述
IDCases. 2023 Jan 20;31:e01703. doi: 10.1016/j.idcr.2023.e01703. eCollection 2023.
2
Omadacycline for the Treatment of Disease: A Case Series.奥马环素治疗疾病：病例系列
Open Forum Infect Dis. 2020 Sep 9;7(10):ofaa415. doi: 10.1093/ofid/ofaa415. eCollection 2020 Oct.
3
Long-term Safety and Tolerability of Omadacycline for the Treatment of Infections.奥马环素治疗感染的长期安全性和耐受性
Open Forum Infect Dis. 2023 Jul 3;10(7):ofad335. doi: 10.1093/ofid/ofad335. eCollection 2023 Jul.
4
Omadacycline for management of Mycobacterium abscessus infections: a review of its effectiveness, place in therapy, and considerations for use.奥马环素治疗脓肿分枝杆菌感染：有效性评价、治疗地位及应用考量。
BMC Infect Dis. 2022 Nov 22;22(1):874. doi: 10.1186/s12879-022-07857-7.
5
Omadacycline in first-line combination therapy for pulmonary Mycobacterium abscessus infection: a case series.奥马环素一线联合治疗肺脓肿分枝杆菌感染：病例系列研究。
Int J Infect Dis. 2022 Sep;122:953-956. doi: 10.1016/j.ijid.2022.06.061. Epub 2022 Jul 4.
6
Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus.奥马环素作为一种有前途的新型药物，可用于治疗脓肿分枝杆菌感染。
J Antimicrob Chemother. 2019 Oct 1;74(10):2930-2933. doi: 10.1093/jac/dkz267.
7
Potency of Omadacycline against Mycobacteroides abscessus Clinical Isolates and in a Mouse Model of Pulmonary Infection.奥马环素对脓肿分枝杆菌临床分离株的效价及肺部感染小鼠模型的疗效。
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0170421. doi: 10.1128/AAC.01704-21. Epub 2021 Oct 18.
8
Omadacycline Potentiates Clarithromycin Activity Against .奥马环素增强克拉霉素对……的活性。 （原文结尾不完整）
Front Pharmacol. 2021 Dec 8;12:790767. doi: 10.3389/fphar.2021.790767. eCollection 2021.
9
Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of .新型四环素类似物奥马环素和依拉环素对.耐药临床分离株的活性
Antimicrob Agents Chemother. 2019 May 24;63(6). doi: 10.1128/AAC.00470-19. Print 2019 Jun.
10
Susceptibility Testing of Omadacycline against Nontuberculous Mycobacteria.奥马环素对非结核分枝杆菌的药敏试验。
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.01947-20.

引用本文的文献

1
New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on ).抗菌药物新视角：奥马环素用于社区获得性肺炎、皮肤及软组织感染和非结核分枝杆菌（重点论述）
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0108724. doi: 10.1128/aac.01087-24. Epub 2025 Jan 16.
2
activity of omadacycline against clinical isolates of .奥马环素对.临床分离株的活性。
Antimicrob Agents Chemother. 2024 May 2;68(5):e0168623. doi: 10.1128/aac.01686-23. Epub 2024 Mar 27.
3
Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant in the hollow fiber system model.奥马环素的药代动力学/药效学及在中空纤维系统模型中对多重耐药菌的疗效。
Antimicrob Agents Chemother. 2024 Feb 7;68(2):e0108023. doi: 10.1128/aac.01080-23. Epub 2023 Dec 22.
4
Safety and tolerability of long-term use of omadacycline in the treatment of infections.奥马环素长期用于治疗感染的安全性和耐受性。
IDCases. 2023 Jul 5;33:e01843. doi: 10.1016/j.idcr.2023.e01843. eCollection 2023.

本文引用的文献

1
Omadacycline Potentiates Clarithromycin Activity Against .奥马环素增强克拉霉素对……的活性。 （原文结尾不完整）
Front Pharmacol. 2021 Dec 8;12:790767. doi: 10.3389/fphar.2021.790767. eCollection 2021.
2
Potency of Omadacycline against Mycobacteroides abscessus Clinical Isolates and in a Mouse Model of Pulmonary Infection.奥马环素对脓肿分枝杆菌临床分离株的效价及肺部感染小鼠模型的疗效。
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0170421. doi: 10.1128/AAC.01704-21. Epub 2021 Oct 18.
3
: A Review of Recent Developments in an Emerging Pathogen.一种新兴病原体的最新研究进展综述。
Front Cell Infect Microbiol. 2021 Apr 26;11:659997. doi: 10.3389/fcimb.2021.659997. eCollection 2021.
4
Preliminary, Real-world, Multicenter Experience With Omadacycline for Infections.奥马环素治疗感染的初步、真实世界、多中心经验
Open Forum Infect Dis. 2021 Jan 7;8(2):ofab002. doi: 10.1093/ofid/ofab002. eCollection 2021 Feb.
5
Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases.非结核分枝杆菌病的流行病学、诊断与治疗。
Indian J Med Res. 2020 Sep;152(3):185-226. doi: 10.4103/ijmr.IJMR_902_20.
6
Omadacycline for the Treatment of Disease: A Case Series.奥马环素治疗疾病：病例系列
Open Forum Infect Dis. 2020 Sep 9;7(10):ofaa415. doi: 10.1093/ofid/ofaa415. eCollection 2020 Oct.
7
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.非结核分枝杆菌肺病的治疗：美国胸科学会/欧洲呼吸学会/欧洲临床微生物学与感染病学会/美国感染病学会官方临床实践指南
Eur Respir J. 2020 Jul 7;56(1). doi: 10.1183/13993003.00535-2020. Print 2020 Jul.
8
Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?替加环素在治疗非结核分枝杆菌病方面有作用吗？
J Antimicrob Chemother. 2020 Mar 1;75(3):609-617. doi: 10.1093/jac/dkz511.
9
Utilizing the Promise of Omadacycline in a Resistant, Non-tubercular Mycobacterial Pulmonary Infection.利用奥马环素治疗耐药性非结核分枝杆菌肺部感染的前景
Cureus. 2019 Jul 9;11(7):e5112. doi: 10.7759/cureus.5112.
10
Clinical Efficacy and Adverse Effects of Antibiotics Used to Treat Pulmonary Disease.用于治疗肺部疾病的抗生素的临床疗效及不良反应
Front Microbiol. 2019 Aug 23;10:1977. doi: 10.3389/fmicb.2019.01977. eCollection 2019.

奥马环素用于治疗感染：病例系列及文献综述

Omadacycline for the treatment of infections: Case series and review of the literature.

作者信息

Siddiqa Ayesha, Khan Shanza, Rodriguez George D, Urban Carl, Segal-Maurer Sorana, Turett Glenn

机构信息

Department of Medicine, NewYork-Presbyterian Queens, 56-45 Main St., Flushing, NY 11355, United States of America.

The Dr. James J. Rahal, Jr. Division of Infectious Diseases, NewYork-Presbyterian Queens, 56-45 Main St., Flushing, NY 11355, United States of America.

出版信息

IDCases. 2023 Jan 20;31:e01703. doi: 10.1016/j.idcr.2023.e01703. eCollection 2023.

DOI:10.1016/j.idcr.2023.e01703
PMID:36747912
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9898728/
Abstract

Treatment of infections are problematic due to inherent multidrug resistance and lack of response to antibacterials commonly used as therapy for other mycobacterial infections. We report the clinical success of five patients who received definitive-treatment with an omadacycline-containing combination regimen for infection.

摘要

由于固有的多重耐药性以及对常用于治疗其他分枝杆菌感染的抗菌药物缺乏反应， 感染的治疗存在问题。我们报告了五名患者接受含奥马环素联合方案进行 感染确定性治疗的临床成功案例。